指南与共识垂体与肾上腺疾病

单侧原发性醛固酮增多症肾上腺切除术后的结局:结局指标国际共识及国际队列缓解率分析

Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort.
指南 / 共识 · Lancet Diabetes Endocrinol · 2017-05-30

PASO研究通过31位专家Delphi法制定单侧原发性醛固酮增多症肾上腺切除术后临床与生化结局的共识标准,并回顾性分析9国12中心705例患者。完全临床成功259例(37%),部分临床成功334例(47%),完全生化成功656/699例(94%)。女性、年轻及术前用药少者完全临床成功可能性更高。

要点

  • 共识定义了六类结局(临床与生化的完全、部分、无成功)及两项随访时机推荐。
  • 国际队列中完全临床成功37%、部分临床成功47%、完全生化成功94%。
  • 女性、年轻患者完全临床成功可能性更高,术前用药多者更低。

核心结论

  • 这些标准化结局标准适用于评估个体患者手术治疗的成功,并允许未来研究比较结局数据。
  • 国际队列基线临床特征差异大导致临床结局变异宽泛。
  • 多数患者从肾上腺切除术中获得临床获益,年轻和女性患者更可能获得良好手术结局。
  • 每个符合美国内分泌学会指南标准者均应筛查原发性醛固酮增多症,因为无临床成功的生化成功本身具有临床重要性,且老年女性和男性也可获得术后临床获益。

研究设计与样本

  • PASO研究为国际项目,由28个中心31位专家(含6位内分泌外科医生)采用Delphi法达成共识。
  • 随后回顾性分析前瞻性队列的随访数据,纳入9国12个转诊中心1994至2015年间连续入选、经肾上腺静脉采血诊断单侧原发性醛固酮增多症并接受全肾上腺切除术的患者。
  • 分析临床数据705例,其中699例有生化数据。
  • 采用logistic回归分析术前因素与临床及生化结局的关联。

主要发现

  • 完全临床成功259/705例(37%,范围17-62),部分临床成功另334例(47%,范围35-66)。
  • 完全生化成功656/699例(94%,范围83-100)。
  • 女性较男性完全临床成功可能性更高(OR 2.25,95%CI 1.40-3.62;p=0.001),临床获益(完全加部分临床成功)可能性更高(OR 2.89,95%CI 1.49-5.59;p=0.002)。
  • 年龄每增加1岁,完全临床成功可能性降低(OR 0.95,95%CI 0.93-0.98;p<0.001),临床获益可能性降低(OR 0.95,95%CI 0.92-0.98;p=0.004)。
  • 术前用药水平每增加1单位,完全临床成功可能性降低(OR 0.80,95%CI 0.70-0.90;p<0.001)。

关键数值与推荐

  • 共识达成基于血压、抗高血压药物使用、血钾和醛固酮浓度、血浆肾素浓度或活性的六类结局标准(临床与生化的完全、部分、无成功)。
  • 共识达成两项关于随访评估时机的推荐。

临床怎么用

  • 标准化结局标准可用于评估个体患者手术治疗的成功并比较未来研究结局数据。
  • 每个符合美国内分泌学会指南标准者均应筛查原发性醛固酮增多症。
  • 老年女性和男性也可获得术后临床获益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although unilateral primary aldosteronism is the most common surgically correctable cause of hypertension, no standard criteria exist to classify surgical outcomes. We aimed to create consensus criteria for clinical and biochemical outcomes and follow-up of adrenalectomy for unilateral primary aldosteronism and apply these criteria to an international cohort to analyse the frequency of remission and identify preoperative determinants of successful outcome. METHODS: The Primary Aldosteronism Surgical Outcome (PASO) study was an international project to develop consensus criteria for outcomes and follow-up of adrenalectomy for unilateral primary aldosteronism. An international panel of 31 experts from 28 centres, including six endocrine surgeons, used the Delphi method to reach consensus. We then retrospectively analysed follow-up data from prospective cohorts for outcome assessment of patients diagnosed with unilateral primary aldosteronism by adrenal venous sampling who had undergone a total adrenalectomy, consecutively included from 12 referral centres in nine countries. On the basis of standardised criteria, we determined the proportions of patients achieving complete, partial, or absent clinical and biochemical success in accordance with the consensus. We then used logistic regression analyses to identify preoperative factors associated with clinical and biochemical outcomes. FINDINGS: Consensus was reached for criteria for six outcomes (complete, partial, and absent success of clinical and biochemical outcomes) based on blood pressure, use of antihypertensive drugs, plasma potassium and aldosterone concentrations, and plasma renin concentrations or activities. Consensus was also reached for two recommendations for the timing of follow-up assessment. For the international cohort analysis, we analysed clinical data from 705 patients recruited between 1994 and 2015, of whom 699 also had biochemical data. Complete clinical success was achieved in 259 (37%) of 705 patients, with a wide variance (range 17-62), and partial clinical success in an additional 334 (47%, range 35-66); complete biochemical success was seen in 656 (94%, 83-100) of 699 patients. Female patients had a higher likelihood of complete clinical success (odds ratio [OR] 2·25, 95% CI 1·40-3·62; p=0·001) and clinical benefit (complete plus partial clinical success; OR 2·89, 1·49-5·59; p=0·002) than male patients. Younger patients had a higher likelihood of complete clinical success (OR 0·95 per extra year, 0·93-0·98; p<0·001) and clinical benefit (OR 0·95 per extra year, 0·92-0·98; p=0·004). Higher levels of preoperative medication were associated with lower levels of complete clinical success (OR 0·80 per unit increase, 0·70-0·90; p<0·001). INTERPRETATION: These standardised outcome criteria are relevant for the assessment of the success of surgical treatment in individual patients and will allow the comparison of outcome data in future studies. The variable baseline clinical characteristics of our international cohort contributed to wide variation in clinical outcomes. Most patients derive clinical benefit from adrenalectomy, with younger patients and female patients more likely to have a favourable surgical outcome. Screening for primary aldosteronism should nonetheless be done in every individual fulfilling US Endocrine Society guideline criteria because biochemical success without clinical success is by itself clinically important and older women and men can also derive post-operative clinical benefit. FUNDING: European Research Council; European Union's Horizon 2020; Else Kröner-Fresenius Stiftung; Netherlands Organisation for Health Research and Development-Medical Sciences; Japanese Ministry of Health, Labour and Welfare; Ministry of Health, Slovenia; US National Institutes of Health; and CONICYT-FONDECYT (Chile).

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Williams TA, Lenders JWM, Mulatero P, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017. PMID: 28576687. doi:10.1016/S2213-8587(17)30135-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。